Royalty Report: Drugs, Cancer, Diagnostic – Collection: 5202


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Cancer
  • Diagnostic
  • Biotechnology
  • Immune
  • Assay
  • Antibody
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 5202

License Grant
The University granted the Licensee an exclusive right and license to utilize the Licensed Technology to develop the Licensed Products.
License Property
The patented technology refers Thymidine Kinase Isoenzyme Diagnostics and Thymidine Kinase Hybridomas. Thymidine Kinase – 1 or TK1 is a cancer screening technology.  A kit using the ELISA format, would require only a small blood sample and could also be incorporated into a standard blood test panel. The ELISA format is a fundamental tool of clinical immunology, based on the principle of antibody-antibody interaction.   A kit using this format provides easy visualization of results, detecting the presence and amount of TK1, and can be completed without the expense and other problems of using radioactive materials.

Thymidine kinase is an enzyme, a phosphotransferase (a kinase) 2'-deoxythymidine kinase, ATP-thymidine 5'-phosphotransferase, EC[2][3] It can be found in most living cells. It is present in two forms in mammalian cells, TK1 and TK2. Certain viruses also have genetic information for expression of viral thymidine kinases.

Thymidine Kinase-1, or TK1, test may enable early detection and monitoring of several types of common cancers in an efficient and cost effective manner.

The BIOLOGICAL MATERIAL known as 'Thymidine Kinase Hybridomas' consists of the following hybridoma cell line clones which produce anti-thymidine kinase monoclonal antibodies.

Field of Use
The Licensee shall develop a serum Enzyme-Linked Immunosorbent Assay (ELISA) diagnostic kit for the detection of Thymidine Kinase-1 Isoenzyme.

IPSCIO Record ID: 211874

License Grant
Licensor grants to the Australian Licensee a non-transferable, non-exclusive, perpetual and irrevocable license under the Patent to make, have made, use, sell, offer to sell, and import canine heartworm test kit products (CHW Kits) that contain the anti-CHW monoclonal antibody from clone key DI 16 872.5 (the CHW Antibody) or any derivatives thereof created or developed by or for Licensee (the CHW Antibody Derivatives).

Licensor further grants a non-transferable, non-exclusive, perpetual and irrevocable license under the Patent to use, sell, offer to sell, and import CHW Antibody contained in CHW Kits; and, CHW Antibody Derivatives contained in CHW Kits.

Licensee shall have no right to sublicense.

Licensor grants Licensee an immunity from suit for licensed products.

Licensor grants an exclusive, non-transferable, sublicensable (only to Licensee partners) license, to use and display  Japan Witness® trademark only for ICT lateral flow veterinary test kit products sold in Japan. With regard to this license, Licensee shall not, and shall have no right to, sell outside of Japan, or authorize its distributors, resellers, and OEMs to sell outside of Japan, ICT lateral flow veterinary test kit products bearing Japan Witness® trademark.

License Property
The patent is for Immunoassay for Anti-Dirofilaria Immitis Antibody.  

The biological materials are Anti-CHW MAb, clone key DI16872.5-USDA code E118.00, Rabbit Anti-CHW PAb-USDA code E019.00, Rabbit Anti-CPV PAb-USDA code E024.01, and, Anti-CPV MAb, clone key A1C2.32-USDA code E024.01.

The products are canine heartworm test kits.

Field of Use
Licensee is in the business of developing, manufacturing and marketing veterinary diagnostics and other animal health related products worldwide, including ICT lateral flow veterinary test kit products which, for purposes of this Agreement, shall mean all veterinary diagnostic products in ICT (immunochromatography strip assay) format.

IPSCIO Record ID: 27645

License Grant
Japanese Licensor grants to Licensee and its Affiliates the sole and exclusive, world-wide, royalty-bearing, assignable license under the Licensed Patents and Related Materials, with right to sublicense in one or more tiers of sublicenses, to research, develop, make, have made, use, sell, offer for sale, and import products and/or services in any and all fields of use or application.
License Property
Licensor owns certain rights in and to certain patents, information and materials related to the human antibody Pritumumab and a sister antibody to Pritumumab.

Licensed Patents
Patents on pritumumab (aka, CLNH11/CLNIgG; plus CLNH5)
4,618,577 – human-human hybridoma, CLNH5

4,761,377 – human-human hybrid cell lines that produce antibodies against antigenic determinants on cancer cells

5,093,261 – cancer-related antigen-specific human immunoglobulins and human/human hybridomas having the ability to produce said human immunoglobulins

5,155,036 – serum-free medium containing retinoic acid useful for cultivating human/human hybridomas

5,286,647 – human-human hybridomas for neoplasms

5,589,573 – amino acid sequences of anti-idiotypic antibodies against anti-cancer human monoclonal antibody, and DNA base sequences encoding those sequences.

5,602,027 – cell line TRIH8 obtained by the fusion of the human epidermoid carcinoma cell line A431 with the TOS/H8 hybridoma.

6,051,229 – human-humann hybridoma for neoplasms CLNH5 and CLNH11 specific antibody compositions

6,051,387 – methods of determining the presence of a neoplasm with CLNH5- and CLNH11-specific antibodies

6,051,693 – CLNH11-specific antibodies

6,090,924 – human-human CLNH5-specific antibodies

6,165,467 – stabilized human monoclonal antibody preparation

Field of Use
Pritumumab is a human monoclonal antibody[1] used in the treatment of brain cancer.

The goal of the Licensee is to become a leading oncology-focused biopharmaceutical company

IPSCIO Record ID: 5622

License Grant
The Licensor hereby grants an exclusive license without the right to grant sublicenses in the Territory to the Licensed Intellectual Property to (a) confirm performance of the Colon 101 ELISA Test and (b) use the Colon 101 ELISA Test to offer and provide services within the cDx Field and the rDx Field.

Licensee and its Affiliates shall have the right to use the Trademarks, solely in connection with the use of the Colon 101 ELISA Test.

CDX field means clinical diagnostic testing services performed by a reference laboratory using a test on human samples, the results of which are provided to hospitals, physicians, payers, and/or patients for use in the clinical management of patients.

RDX Field means use in vitro diagnostic testing services in Clinical Trials.

The Licensee shall have the right to use the Trademarks.

License Property
The Licensor has developed a blood test known as the Colon 101 ELISA Test  to detect and quantify the Colon 101 protein in serum.
Field of Use
'CDX Field' means clinical diagnostic testing services performed by a reference laboratory using a test on human samples, the results of which are provided to hospitals, physicians, payers, and/or patients for use in the clinical management of patients.

'RDX Field' means use in in vitro diagnostic testing services in Clinical Trials.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.